Tuberous Sclerosis Complex Clinical Trial
Official title:
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
NCT number | NCT02687633 |
Other study ID # | 15-000699 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2015 |
Est. completion date | August 2017 |
Verified date | April 2018 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators are running an intervention study for young children with Tuberous
Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that
may improve social and communication skills in children with TSC. Eligible families will have
a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be
available to attend the weekly intervention sessions at UCLA.
The intervention will focus on teaching caregivers skills to improve the social and
communication outcomes of their children. The content of the intervention will be
individually tailored to the child's developmental level. The intervention involves
pre-assessments, an intervention period of daily 60 minute sessions for 10 days, followed by
weekly 60 minute sessions for 10 weeks, and post-assessments. The classroom can have up to 3
parent-child dyad and the curriculum focuses on improving social-communication and play
skills.
Status | Completed |
Enrollment | 8 |
Est. completion date | August 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Months to 36 Months |
Eligibility |
Inclusion Criteria: - A confirmed diagnosis of Tuberous Sclerosis Complex Exclusion Criteria: - A mental age less than 6 months. A plan for epilepsy surgery during the study participation period. |
Country | Name | City | State |
---|---|---|---|
United States | UCLA Semel Insitute | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | Boston Children’s Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change from baseline in Joint Engagement (shared engagement in a play routine) at 2 weeks into study participation, according to the parent caregiver interaction assessment. | Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine. | 2 weeks | |
Primary | change from baseline in Joint Engagement (shared engagement in a play routine) at 3 months into study participation, according to the parent caregiver interaction assessment. | Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine. | 3 months | |
Primary | change from baseline in Joint Engagement (shared engagement in a play routine) at 6 months into study participation, according to the parent caregiver interaction assessment. | Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine. | 6 months | |
Secondary | Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 2 weeks | ESCS (Early Social Communication Scales) Assessment. | 2 weeks | |
Secondary | Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 3 months | ESCS (Early Social Communication Scales) Assessment. | 3 months | |
Secondary | Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 6 months | ESCS (Early Social Communication Scales) Assessment. | 6 months | |
Secondary | Change from baseline in Symbolic Play (types of play and level of play) at 2 weeks, according to the Structured Play Assessment (SPA) | The Structured Play Assessment measures the child's play level, based on distinct sets of toys that target specific developmental markers of play. | 2 weeks | |
Secondary | Change from baseline in Symbolic Play (types of play and level of play) at 3 months, according to the Structured Play Assessment (SPA) | The Structured Play Assessment measures the child's play level, based on distinct sets of toys that target specific developmental markers of play. | 3 months | |
Secondary | Change from baseline in Symbolic Play (types of play and level of play) at 6 months, according to the Structured Play Assessment (SPA) | The Structured Play Assessment measures the child's play level, based on distinct sets of toys that target specific developmental markers of play. | 6 months | |
Secondary | Change from baseline at 3 months in developmental quotient, as determined by the Mullen Scales of Early Learning | Cognition will be determined by a Developmental Quotient on a traditional cognitive measure, the Mullen Scales of Early Learning | 3 months | |
Secondary | Change from baseline at 6 months in developmental quotient, as determined by the Mullen Scales of Early Learning | Cognition will be determined by a Developmental Quotient on a traditional cognitive measure, the Mullen Scales of Early Learning | 6 months | |
Secondary | Change from baseline at 2 weeks in the amount of Parent use of social communication support strategies | Parent use of social communication support strategies as taught by JASPER will be measured by a parent-child interaction assessment. | 2 weeks | |
Secondary | Change from baseline at 3 months in the amount of Parent use of social communication support strategies | Parent use of social communication support strategies as taught by JASPER will be measured by a parent-child interaction assessment. | 3 months | |
Secondary | Change from baseline at 6 months in the amount of Parent use of social communication support strategies | Parent use of social communication support strategies as taught by JASPER will be measured by a parent-child interaction assessment. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
Recruiting |
NCT01730209 -
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
Recruiting |
NCT04987463 -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
|
Phase 2/Phase 3 | |
Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
Recruiting |
NCT06392009 -
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
Active, not recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 | |
Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|